AR and prostate carcinoma: In the case of AR, the molecule EPI–001 and its derivatives bind to the AR-NTD and have been presented as potential drugs that promote the regression of prostate cancer, a disease that is essentially under the regulation of the androgen receptor (AR) [6–8].